Newest Weight Loss Drugs of 2026: What’s Actually Here

The weight loss drug shelf looks different in 2026 than it did even a year ago. The two newest approvals are oral options: an oral semaglutide pill for obesity (approved late 2025) and orforglipron, sold as Foundayo, a once-daily pill approved in April 2026. Several more are close behind, including CagriSema under FDA review and retatrutide still in trials. Among injectables, tirzepatide (Zepbound) and semaglutide (Wegovy) remain the established options. Here’s what’s new, what’s coming, and what you can actually start now.

The Newest Approvals

Two oral drugs headline the recent wave. An oral semaglutide pill for obesity reached the market in late 2025, offering a needle-free version of a familiar molecule. Then in April 2026, the FDA approved orforglipron (Foundayo), the first small-molecule GLP-1 pill that can be taken any time of day without food or water restrictions.

Orforglipron earned its approval on solid trial data. In the ATTAIN-1 trial published in the New England Journal of Medicine in 2025, people at the highest dose lost about 12.4% of their body weight, and the drug carries a boxed warning for thyroid C-cell tumor risk along with the usual gastrointestinal side effects. Both of these oral options are available through their manufacturers rather than through TrimRx, and neither is yet approved for type 2 diabetes.

What’s Under Review or in Trials

CagriSema, a weekly injection combining an amylin analog with semaglutide, has finished its main trials and sits under FDA review, with roughly 22.7% weight loss in its obesity trial. Retatrutide, a triple-hormone injectable, has shown even larger weight loss in early phase 3 readouts (around 24% or more), but it remains investigational, with an FDA submission expected later. Amycretin, available in both oral and injectable forms, is in phase 3. All three are investigational or not yet cleared, so their numbers should be read as preliminary and they aren’t something to count on today.

What You Can Start Now

The newest approvals are exciting, but the most established, available injectable options remain tirzepatide and semaglutide. TrimRx prescribes compounded semaglutide and compounded tirzepatide along with the brand injectables (Ozempic, Wegovy, Mounjaro, Zepbound), so if you’re ready to begin rather than wait for the next launch, there are effective choices available now. You can read more on the TrimRx homepage.

Consider a hypothetical patient weighing whether to wait for a newer pill or start now. Given that the strongest results still come from the established injectables, and that the newest pills are somewhat less potent on average, starting a proven option today is often the more practical path, with the choice reviewed by a provider.

Frequently Asked Questions

What is the newest weight loss drug in 2026?

The most recent approval is orforglipron (Foundayo), a once-daily pill cleared in April 2026, following an oral semaglutide pill approved in late 2025. Both are oral GLP-1 options available through their manufacturers.

Is retatrutide available yet?

No. Retatrutide has shown large weight loss in trials but remains investigational, with FDA submission expected later. It isn’t available for prescription.

Should I wait for a newer drug or start now?

The most effective available options remain tirzepatide and semaglutide. Because newer pills are generally less potent on average, many people start a proven option now rather than wait, with a provider’s guidance.

To explore the options available to you now, you can take the TrimRx quiz for a licensed provider’s review.

This article is for educational purposes and is not medical advice. CagriSema, retatrutide, and amycretin are investigational and not FDA-approved. Orforglipron and oral semaglutide are available through their manufacturers, not TrimRx. Individual results vary.